Analysis of more than 880 clinical trials shows that while statistical data monitoring and key risk indicator signals close on similar timelines, durability—not speed—is the defining differentiator in effective, risk-based quality management.
Melissa Thomas
Advertisement
Central Monitor Consultant, CluePoints
Articles by Melissa Thomas
To maximize the impact of signal detection, KRI frameworks should follow a few guiding principles.
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on Applied Clinical Trials Online
1
FDA RWE Guidance Redefines Data Use in Clinical Operations
2
If You Build It ... Will They Come?
3
Congressional Funding Deal Boosts Research Space Ahead of Shutdown Deadline
4
ACT Brief: Global Trials Scale Up, Site-Centric Startup Gains Focus, and Pfizer Expands Vaccine Partnerships
5